Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepu Madduri

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Nature Medicine|August 17, 2023
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trialYi Lin, Noopur S Raje, Jesús G Berdeja, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2022
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled TrialGerard J Criner, Frederick M Lang, Robert L Gottlieb, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphomaSharmila Raghunandan, Melinda Pauly, William G Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Blood Cancer Journal|February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesAdam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Nature Medicine|August 17, 2023
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trialYi Lin, Noopur S Raje, Jesús G Berdeja, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2022
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled TrialGerard J Criner, Frederick M Lang, Robert L Gottlieb, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphomaSharmila Raghunandan, Melinda Pauly, William G Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Blood Cancer Journal|February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesAdam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Pageof 5